Eli Lilly and Company is looking to boost supplies of its obesity drug Zepbound (tirzepatide) by offering single-dose vials of the drug through its self-pay channel, at a cost that it described as being at least 50% less than other incretin medicines for obesity.
The Indianapolis-based drug maker said 27 August that it would make 2.5mg and 5mg single-dose vials of Zepbound available for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?